Off-Label Ketamine and Out-of-Pocket Expenses

Many clinics offer intravenous (IV), intramuscular (IM), or sublingual ketamine for mental health conditions. Since these specific administrative routes are generally considered off-label for psychiatric use, most insurance plans do not cover them. Patients typically pay out-of-pocket for these therapies. When budgeting, it is important to factor in the total number of recommended sessions and potential maintenance visits. Prospective patients should request a detailed written estimate from their provider before starting treatment. Additionally, patients should familiarize themselves with the FDA warnings about potential risks associated with compounded ketamine products.

Spravato Insurance Coverage

Spravato (esketamine) is an FDA-approved prescription nasal spray specifically indicated for adults with treatment-resistant depression or depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior. Because of its FDA approval, Spravato is more likely to be covered by health insurance. However, coverage varies widely and often requires prior authorization, as well as evidence that other antidepressant treatments have been ineffective. Patients should consult their insurance provider and their clinic’s billing department to understand copayments, deductibles, and any associated transportation costs required for repeated visits to the clinic.

Clinical Assessments and Transportation

Initiating treatment requires a thorough psychiatric and medical assessment to determine if ketamine or esketamine therapy is appropriate. This is followed by a treatment phase that involves multiple repeated visits over several weeks, plus ongoing follow-up evaluations. Because these medications can cause sedation and temporary dissociative effects, patients are strictly prohibited from driving themselves home. A responsible adult must be available to provide transportation after every session. Summer heat in the Phoenix metro area should also be factored into travel planning to ensure comfort after treatment.

Telehealth may be used for assessments or follow-up, but it does not establish that a clinic offers home treatment. Spravato must be administered in a certified healthcare setting with at least two hours of observation. Some clinicians prescribe other ketamine formulations off-label for home use; those products are not FDA-approved for psychiatric treatment, and the FDA warns about compounded ketamine risks, especially without on-site monitoring. Confirm the formulation, setting and safety plan with the prescriber; never assume infusion or Spravato services are offered remotely.

Spravato Safety Protocols and Crisis Support

Spravato must be administered in a medically certified healthcare setting. Under the Risk Evaluation and Mitigation Strategy (REMS) program, patients are monitored by healthcare professionals for at least two hours after receiving the nasal spray. Patients cannot drive or operate heavy machinery until the day following treatment, after a restful sleep. If you or a loved one is experiencing a mental health emergency, immediate help is available. You can call the Arizona statewide crisis line at 1-844-534-4673 (available 24/7) or dial the national 988 Suicide & Crisis Lifeline.